At a contentious meeting with possible implications for other rare disease drugmakers, outside experts ultimately determined ...

Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall ...

Vertex Pharmaceuticals has struck a deal with AbCellera to develop new types of T-cell engagers for autoimmune diseases and, ...

The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public ...

Replimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug. Elsewhere, investors had a muted reaction to a first-of-its-kind study result.

High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.

Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.

The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss ...

In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of six of the seven ...

Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with ...

Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more ...

Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company ...